9,055 Icon Plc $ICLR Shares Sold by State of Wyoming

State of Wyoming cut its stake in Icon Plc (NASDAQ:ICLR) by 40.7% in the 3rd quarter, Holdings Channel reports. The fund owned 13,173 shares of the medical research company’s stock after selling 9,055 shares during the quarter. Icon comprises about 0.2% of State of Wyoming’s holdings, making the stock its 24th largest position. State of Wyoming’s holdings in Icon were worth $2,239,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Principal Financial Group Inc. raised its position in Icon by 10.3% during the first quarter. Principal Financial Group Inc. now owns 3,311,771 shares of the medical research company’s stock valued at $366,481,000 after purchasing an additional 310,236 shares in the last quarter. Trinity Street Asset Management LLP boosted its holdings in shares of Icon by 27.1% in the 2nd quarter. Trinity Street Asset Management LLP now owns 1,535,462 shares of the medical research company’s stock worth $266,725,000 after purchasing an additional 327,314 shares in the last quarter. Maple Rock Capital Partners Inc. increased its position in shares of Icon by 257.8% during the 2nd quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company’s stock valued at $208,383,000 after purchasing an additional 864,300 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Icon by 50.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 788,828 shares of the medical research company’s stock valued at $87,262,000 after purchasing an additional 265,858 shares during the last quarter. Finally, Sound Shore Management Inc. CT purchased a new position in shares of Icon during the 1st quarter valued at about $69,379,000. Institutional investors own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ICLR shares. TD Cowen boosted their target price on Icon from $197.00 to $254.00 and gave the stock a “buy” rating in a research report on Thursday. Robert W. Baird upped their target price on Icon from $210.00 to $249.00 and gave the stock an “outperform” rating in a research note on Thursday. Jefferies Financial Group reissued a “buy” rating and set a $254.00 price target on shares of Icon in a research note on Thursday. Evercore restated an “outperform” rating and issued a $240.00 price objective on shares of Icon in a report on Wednesday. Finally, Mizuho set a $228.00 price objective on shares of Icon in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $213.76.

Insider Transactions at Icon

In other news, Director Ronan Murphy sold 5,005 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $175.00, for a total transaction of $875,875.00. Following the completion of the sale, the director owned 3,847 shares of the company’s stock, valued at approximately $673,225. This represents a 56.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ciaran Murray sold 2,677 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total value of $439,804.33. Following the sale, the director directly owned 20,452 shares of the company’s stock, valued at approximately $3,360,059.08. This trade represents a 11.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 23,068 shares of company stock valued at $3,936,744. Insiders own 44.00% of the company’s stock.

Icon Stock Down 1.9%

ICLR opened at $211.36 on Friday. Icon Plc has a 12 month low of $66.57 and a 12 month high of $219.04. The company has a current ratio of 1.32, a quick ratio of 0.95 and a debt-to-equity ratio of 0.37. The business’s 50-day moving average price is $171.97 and its 200-day moving average price is $146.52. The company has a market cap of $16.18 billion, a P/E ratio of 36.38, a P/E/G ratio of 13.93 and a beta of 1.24.

Icon (NASDAQ:ICLR) last issued its earnings results on Tuesday, October 27th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.62 by $0.04. Icon had a return on equity of 7.73% and a net margin of 5.45%. The company had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $2.01 billion. During the same period in the prior year, the business posted $3.31 EPS. Icon’s quarterly revenue was down .9% compared to the same quarter last year. On average, equities analysts expect that Icon Plc will post 9.55 EPS for the current year.

Icon Profile

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.